SCHEMBL2642615

SCHEMBL2642615

Cc1cnc(-c2nc(N)c3cc(Sc4ncccc4Cl)ccc3n2)cn1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD1 P21728 1/20 0.36
KDM4E B2RXH2 5/20 0.35
KMT2A Q03164 4/20 0.35
MAPT P10636 2/20 0.35
LMNA P02545 2/20 0.35
NPSR1 Q6W5P4 2/20 0.35
PKM P14618 1/20 0.35
MAPK1 P28482 1/20 0.35
MCL1 Q07820 1/20 0.35
ALDH1A1 P00352 6/20 0.35
HPGD P15428 2/20 0.35
MEN1 O00255 2/20 0.35
CYP1A2 P05177 3/20 0.34
CYP3A4 P08684 2/20 0.34
CYP2C9 P11712 2/20 0.34
CYP2C19 P33261 2/20 0.34
GRM5 P41594 2/20 0.34
USP2 O75604 1/20 0.32
CYP2D6 P10635 1/20 0.32
TSHR P16473 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2642439 0.82 DRD1 (0.38) DRD1KDM4EKMT2AMAPTLMNA
SCHEMBL2642307 0.81 KDM4E (0.36) DRD1KDM4EKMT2AMAPTLMNA
SCHEMBL2642893 0.64 KDM4E (0.36) KDM4EKMT2AMAPTLMNANPSR1
SCHEMBL11862826 0.62 L3MBTL1 (0.57) KDM4EKMT2AMAPTLMNAMAPK1
SCHEMBL6121387 0.61 HTR3A (0.45) MAPK1ALDH1A1
SCHEMBL22229495 0.60 ALDH1A1 (0.42) KDM4EKMT2AMAPTNPSR1PKM
SCHEMBL2642341 0.60 GCK (0.35)
SCHEMBL18023076 0.60 POLB (0.49) KMT2ALMNAMAPK1ALDH1A1MEN1
SCHEMBL2642429 0.59 ALDH1A1 (0.36) LMNAALDH1A1
SCHEMBL8386316 0.59 KDM4E (0.58) KDM4EKMT2AMAPTLMNANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7687502-B2 Substituted quinazoline or pyridopyrimidine derivative BANYU PHARMACEUTICAL CO., LTD. (JP) 2010-03-30 US claimed
US-20080032996-A1 Substituted Quinazoline or Pyridopyrimidine Derivative MSD K.K. (JP) 2008-02-07 US claimed
EP-1734040-A1 SUBSTITUTED QUINAZOLINE OR PYRIDOPYRIMIDINE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2006-12-20 EP claimed
US-7687502-B2 Substituted quinazoline or pyridopyrimidine derivative BANYU PHARMACEUTICAL CO., LTD. (JP) 2010-03-30 US disclosed
US-20080032996-A1 Substituted Quinazoline or Pyridopyrimidine Derivative MSD K.K. (JP) 2008-02-07 US disclosed
EP-1734040-A1 SUBSTITUTED QUINAZOLINE OR PYRIDOPYRIMIDINE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2006-12-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080032996-A1 Substituted Quinazoline or Pyridopyrimidine Derivative GCK, GCKR, PDXK DRD1 1956/4885KDM4E 1277/4885KMT2A 1505/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.